Bias in observational studies of prevalent users: Lessons for comparative effectiveness research from a meta-analysis of statins

American Journal of Epidemiology

Volumn 175, Issue 4, 2012, Pages 250-262

  Danaei, Goodarz ^a   Tavakkoli, Mohammad ^a   Hernán, Miguel A ^a,b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b HARVARD UNIVERSITY   (United States)

Author keywords

bias (epidemiology); comparative effectiveness research; confounding factors (epidemiology); meta analysis; prospective studies; selection bias

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

CARDIOVASCULAR DISEASE; COMPARATIVE STUDY; DATA SET; EPIDEMIOLOGY; FEASIBILITY STUDY; HORMONE; META-ANALYSIS; MORTALITY; MULTIVARIATE ANALYSIS; OBSERVATIONAL METHOD; RESEARCH WORK;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMPARATIVE EFFECTIVENESS; DRUG EFFICACY; DRUG USE; DRUG WITHDRAWAL; HEART INFARCTION; HUMAN; META ANALYSIS; MORTALITY; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; REVIEW; SECONDARY PREVENTION; SYSTEMATIC ERROR; SYSTEMATIC REVIEW;

COMPARATIVE EFFECTIVENESS RESEARCH; CONFOUNDING FACTORS (EPIDEMIOLOGY); CORONARY DISEASE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MEDICATION ADHERENCE; OBSERVATION; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SECONDARY PREVENTION; SELECTION BIAS;

EID: 84856694624     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwr301     Document Type: Review

References (106)

1. Alexander GC, Stafford RS. Does comparative effectiveness have a comparative edge? JAMA. 2009;301(23):2488-2490.
2. Avorn J. Debate about funding comparative-effectiveness research. N Engl J Med. 2009;360(19):1927-1929.
3. Iglehart JK. Prioritizing comparative-effectiveness research-IOM recommendations. N Engl J Med. 2009;361(4):325-328.
4. Kuehn BM. Institute of Medicine outlines priorities for comparative effectiveness research. JAMA. 2009;302(9):936-937.
5. Mushlin AI, Ghomrawi H. Health care reform and the need for comparative-effectiveness research. N Engl J Med. 2010; 362(3):e6. (doi:10.1056/NEJMp0912651).
6. Naik AD, Petersen LA. The neglected purpose of comparative-effectiveness research. N Engl J Med. 2009; 360(19):1929-1931.
7. Leng GC. NHS Evidence: better and faster access to information. Lancet. 2009;373(9674):1502-1504.
8. Rawlins MD. The decade of NICE. Lancet. 2009;374(9686): 351-352.
9. MacLehose RR, Reeves BC, Harvey IM, et al. A systematic review of comparisons of effect sizes derived from randomised and non-randomised studies. Health Technol Assess. 2000;4(34):1-154.
10. Furlan AD, Tomlinson G, Jadad AA, et al. Methodological quality and homogeneity influenced agreement between randomized trials and nonrandomized studies of the same intervention for back pain. J Clin Epidemiol. 2008;61(3):209-231.
11. Abraham NS, Byrne CJ, Young JM, et al. Meta-analysis of well-designed nonrandomized comparative studies of surgical procedures is as good as randomized controlled trials. J Clin Epidemiol. 2010;63(3):238-245.
12. Gibbons RJ, Gardner TJ, Anderson JL, et al. The American Heart Association's principles for comparative effectiveness research: a policy statement from the American Heart Association. Circulation. 2009;119(22):2955- 2962.
13. Wilson PW, Garrison RJ, Castelli WP. Postmenopausal estrogen use, cigarette smoking, and cardiovascular morbidity in women over 50. The Framingham Study. N Engl J Med. 1985;313(17):1038-1043. (Pubitemid 16243330)
14. Varas-Lorenzo C, García-Rodríguez LA, Perez-Gutthann S, et al. Hormone replacement therapy and incidence of acute myocardial infarction. A population-based nested case-control study. Circulation. 2000;101(22):2572-2578. (Pubitemid 30350634)
15. Grodstein F, Stampfer MJ, Manson JE, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med. 1996;335(7):453-461. (Pubitemid 26269944)
16. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease.Women's Health Initiative Investigators. N Engl J Med. 2003;349(6):523-534. (Pubitemid 36951364)
17. Hernán MA, Robins JM. García Rodríguez LA. Discussion on "Statistical issues arising in theWomen's Health Initiative." Biometrics. 2005;61(4):922-930. (Pubitemid 43906898)
18. Hernán MA, Alonso A, Logan R, et al. Observational studies analyzed like randomized experiments: an application to postmenopausal hormone therapy and coronary heart disease. Epidemiology. 2008;19(6):766-779.
19. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003;158(9):915-920. (Pubitemid 37323253)
20. Ross SD, Allen IE, Connelly JE, et al. Clinical outcomes in statin treatment trials: a meta-analysis. Arch Intern Med. 1999; 159(15):1793-1802. (Pubitemid 29379144)
21. Cheung BM, Lauder IJ, Lau CP, et al. Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes. Br J Clin Pharmacol. 2004;57(5): 640-651. (Pubitemid 38582185)
22. Simes J, Furberg CD, Braunwald E, et al. Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels. The Prospective Pravastatin Pooling Project. Eur Heart J. 2002;23(3): 207-215. (Pubitemid 36358242)
23. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267- 1278.
24. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA. 1999;282(24):2340-2346. (Pubitemid 30013066)
25. Wilt TJ, Bloomfield HE, MacDonald R, et al. Effectiveness of statin therapy in adults with coronary heart disease. Arch Intern Med. 2004;164(13):1427-1436. (Pubitemid 38937854)
26. Ray KK, Seshasai SR, Erqou S, et al. Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants. Arch Intern Med. 2010;170(12):1024-1031.
27. Mills EJ, Wu P, Chong G, et al. Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials. QJM. 2011; 104(2):109-124.
28. Mills EJ, Rachlis B, Wu P, et al. Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. J Am Coll Cardiol. 2008;52(22):1769-1781.
29. Brugts JJ, Yetgin T, Hoeks SE, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ. 2009;338:b2376. (doi: 10.1136/bmj. b2376).
30. Mora S, Glynn RJ, Hsia J, et al. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials. Circulation. 2010;121(9):1069-1077.
31. Taylor F, Ward K, Moore TH, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2011;(1):CD004816. (doi:10.1002/14651858. CD004816.pub4).
32. Petretta M, Costanzo P, Perrone-Filardi P, et al. Impact of gender in primary prevention of coronary heart disease with statin therapy: a meta-analysis. Int J Cardiol. 2010;138(1): 25-31.
33. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177-188. (Pubitemid 17189972)
34. Egger M, Davey Smith G, Schneider M, et al. Bias in metaanalysis detected by a simple, graphical test. BMJ. 1997; 315(7109):629-634. (Pubitemid 27387172)
35. Thompson SG, Sharp SJ. Explaining heterogeneity in metaanalysis: a comparison of methods. Stat Med. 1999;18(20): 2693-2708. (Pubitemid 29481404)
36. Chikamori T, Sugimoto K, Hamada T, et al. Efficacy of cholesterol-lowering treatment in Japanese elderly patients with coronary artery disease and normal cholesterol level using 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. J Cardiol. 2000;35(2):95-101. (Pubitemid 30133745)
37. Amarenco P, Bogousslavsky J, Callahan A III, et al. High-dose atorvastatin after stroke or transient ischemic attack. Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. N Engl J Med. 2006;355(6):549-559. (Pubitemid 44202151)
38. Athyros VG, Papageorgiou AA, Mercouris BR, et al. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronaryheart-disease Evaluation (GREACE) study. Curr Med Res Opin. 2002;18(4):220-228.
39. Blankenhorn DH, Azen SP, Kramsch DM, et al. Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med. 1993;119(10):969-976.
40. Furberg CD, Pitt B, Byington RP, et al. Reduction in coronary events during treatment with pravastatin. PLAC I and PLAC II Investigators. Pravastatin Limitation of Atherosclerosis in the Coronary Arteries. Am J Cardiol. 1995;76(9):60C-63C.
41. GISSI Prevenzione Investigators (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico). Results of the low-dose (20 mg) pravastatin GISSI Prevenzione trial in 4271 patients with recent myocardial infarction: do stopped trials contribute to overall knowledge? Ital Heart J. 2000;1(12): 810-820.
42. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebocontrolled trial. Lancet. 2002;360(9326):23-33.
43. Koren MJ, Hunninghake DB. Clinical outcomes in managedcare patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the ALLIANCE study. J Am Coll Cardiol. 2004;44(9):1772-1779. (Pubitemid 39424074)
44. LIPID Study Group (Long-term Intervention with Pravastatin in Ischaemic Disease). Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up. Lancet. 2002;359(9315):1379-1387.
45. Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet. 1994;344(8923): 633-638.
46. Nakagawa T, Kobayashi T, Awata N, et al. Randomized, controlled trial of secondary prevention of coronary sclerosis in normocholesterolemic patients using pravastatin: final 5-year angiographic follow-up of the Prevention of Coronary Sclerosis (PCS) study. Int J Cardiol. 2004;97(1):107-114. (Pubitemid 39178531)
47. Ostadal P, Alan D, Vejvoda J, et al. Fluvastatin in the first-line therapy of acute coronary syndrome: results of the multicenter, randomized, double-blind, placebo-controlled trial (the FACStrial). Trials. 2010;11:61. (doi: 10.1186/1745-6215-11-61).
48. Sato H, Kinjo K, Ito H, et al. Effect of early use of low-dose pravastatin on major adverse cardiac events in patients with acute myocardial infarction: the OACIS-LIPID Study. Circ J. 2008;72(1):17-22. (Pubitemid 351413320)
49. Serruys PW, Foley DP, Jackson G, et al. A randomized placebocontrolled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty: final results of the Fluvastatin Angiographic Restenosis (FLARE) Trial. Eur Heart J. 1999;20(1):58-69. (Pubitemid 29027527)
50. Serruys PW, de Feyter P, Macaya C, et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;287(24):3215-3222. (Pubitemid 34686102)
51. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360(9346): 1623-1630. (Pubitemid 35379733)
52. Teo KK, Burton JR, Buller CE, et al. Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: The Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT). Circulation. 2000; 102(15):1748-1754.
53. Yokoi H,Nobuyoshi M,Mitsudo K, et al. Three-year follow-up results of Angiographic Intervention Trial using an HMG-CoA Reductase Inhibitor to Evaluate Retardation of Obstructive Multiple Atheroma (ATHEROMA) study. Circ J. 2005;69(8): 875-883.
54. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344(8934):1383-1389.
55. Colivicchi F, Guido V, Tubaro M, et al. Effects of atorvastatin 80 mg daily early after onset of unstable angina pectoris or non-Q-wave myocardial infarction. Am J Cardiol. 2002;90(8): 872-874.
56. Flaker GC,Warnica JW, Sacks FM, et al. Pravastatin prevents clinical events in revascularized patients with average cholesterol concentrations. Cholesterol and Recurrent Events CARE Investigators. J Am Coll Cardiol. 1999;34(1): 106-112.
57. Riegger G, Abletshauser C, Ludwig M, et al. The effect of fluvastatin on cardiac events in patients with symptomatic coronary artery disease during one year of treatment. Atherosclerosis. 1999;144(1):263-270. (Pubitemid 29259987)
58. Waters D, Higginson L, Gladstone P, et al. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial. Circulation. 1994;89(3): 959-968.
59. Christensen S, Thomsen RW, Johansen MB, et al. Preadmission statin use and one-year mortality among patients in intensive care-a cohort study. Crit Care. 2010;14(2):R29. (doi:10.1186/cc8902).
60. de Liefde II, Hoeks SE, van Gestel YR, et al. Usefulness of hypertensive blood pressure response during a single-stage exercise test to predict long-term outcome in patients with peripheral arterial disease. Am J Cardiol. 2008;102(7):921-926.
61. Feringa HH, Bax JJ, Karagiannis SE, et al. Elderly patients undergoing major vascular surgery: risk factors and medication associated with risk reduction. Arch Gerontol Geriatr. 2009;48(1):116-120.
62. Herrington DM, Vittinghoff E, Lin F, et al. Statin therapy, cardiovascular events, and total mortality in the Heart and Estrogen/Progestin Replacement Study (HERS). Circulation. 2002;105(25):2962-2967. (Pubitemid 34693827)
63. Hippisley-Cox J, Coupland C. Effect of combinations of drugs on all cause mortality in patients with ischaemic heart disease: nested case-control analysis. BMJ. 2005;330(7499): 1059-1063. (Pubitemid 40646559)
64. Karp I, Chen SF, Pilote L. Sex differences in the effectiveness of statins after myocardial infarction. CMAJ. 2007;176(3): 333-338.
65. Kertai MD, Boersma E, Westerhout CM, et al. Association between long-term statin use and mortality after successful abdominal aortic aneurysm surgery. Am J Med. 2004;116(2): 96-103. (Pubitemid 38056662)
66. Kubota N, Kasai T, Miyauchi K, et al. Therapy with statins and aspirin enhances long-term outcome of percutaneous coronary intervention. Heart Vessels. 2008;23(1):35-39. (Pubitemid 351266887)
67. Schanzer A, Hevelone N, Owens CD, et al. Statins are independently associated with reduced mortality in patients undergoing infrainguinal bypass graft surgery for critical limb ischemia. J Vasc Surg. 2008;47(4):774-781.
68. Schillinger M, Exner M, Mlekusch W, et al. Statin therapy improves cardiovascular outcome of patients with peripheral artery disease. Eur Heart J. 2004;25(9):742-748. (Pubitemid 38647934)
69. Ward RP, Leeper NJ, Kirkpatrick JN, et al. The effect of preoperative statin therapy on cardiovascular outcomes in patients undergoing infrainguinal vascular surgery. Int J Cardiol. 2005;104(3):264-268. (Pubitemid 41379059)
70. Weiner MG, Xie D, Tannen RL. Replication of the Scandinavian Simvastatin Survival Study using a primary care medical record database prompted exploration of a new method to address unmeasured confounding. Pharmacoepidemiol Drug Saf. 2008;17(7):661-670.
71. Welten GM, Chonchol M, Hoeks SE, et al. Statin therapy is associated with improved outcomes in vascular surgery patients with renal impairment. Am Heart J. 2007;154(5):954-961. (Pubitemid 350001281)
72. Allen Maycock CA, Muhlestein JB, Horne BD, et al. Statin therapy is associated with reduced mortality across all age groups of individuals with significant coronary disease, including very elderly patients. Intermountain Heart Collaborative Study. J Am Coll Cardiol. 2002;40(10):1777-1785. (Pubitemid 35341956)
73. Carrier M, Cossette M, Pellerin M, et al. Statin treatment equalizes long-term survival between patients with single and bilateral internal thoracic artery grafts. Ann Thorac Surg. 2009;88(3):789-795.
74. Cooke CA, Kirkland SA, Sketris IS, et al. The impact of statins on health services utilization and mortality in older adults discharged from hospital with ischemic heart disease: a cohort study. BMC Health Serv Res. 2009;9:198. (doi:10. 1186/1472-6963-9-198).
75. De Luca G, Suryapranata H, Ottervanger JP, et al. Impact of statin therapy at discharge on 1-year mortality in patients with ST-segment elevation myocardial infarction treated with primary angioplasty. Atherosclerosis. 2006;189(1):186-192. (Pubitemid 44441280)
76. Fintel D, Joyce A, Mackell J, et al. Reduced mortality rates after intensive statin therapy in managed-care patients. Value Health. 2007;10(2):161-169. (Pubitemid 46481143)
77. Furukawa Y, Taniguchi R, Ehara N, et al. Better survival with statin administration after revascularization therapy in Japanese patients with coronary artery disease: perspectives from the CREDO-Kyoto registry. Circ J. 2008;72(12): 1937-1945.
78. Kulik A, Brookhart MA, Levin R, et al. Impact of statin use on outcomes after coronary artery bypass graft surgery. Circulation. 2008;118(18):1785-1792.
79. Leeper NJ, Ardehali R, deGoma EM, et al. Statin use in patients with extremely low low-density lipoprotein levels is associated with improved survival. Circulation. 2007;116(6): 613-618. (Pubitemid 47364579)
80. Muhlestein JB, Anderson JL, Horne BD, et al. Early effects of statins in patients with coronary artery disease and high C-reactive protein. Intermountain Heart Collaborative Study Group. Am J Cardiol. 2004;94(9):1107-1112. (Pubitemid 39424210)
81. Nagashima M, Koyanagi R, Kasanuki H, et al. Effect of early statin treatment at standard doses on long-term clinical outcomes in patients with acute myocardial infarction (the Heart Institute of Japan, Department of Cardiology Statin Evaluation Program). Am J Cardiol. 2007;99(11):1523-1528. (Pubitemid 46770634)
82. Sheng X, Wei L, Murphy MJ, et al. Statins and total (not LDL) cholesterol concentration and outcome of myocardial infarction: results from a meta-analysis and an observational study. Eur J Clin Pharmacol. 2009;65(11):1071-1080.
83. Stenestrand U, Wallentin L. Early statin treatment following acute myocardial infarction and 1-year survival. Swedish Register of Cardiac Intensive Care (RIKS-HIA). JAMA. 2001; 285(4):430-436. (Pubitemid 32097261)
84. Zhang ZJ, Marroquin OC, Weissfeld JL, et al. Beneficial effects of statins after percutaneous coronary intervention. Eur J Cardiovasc Prev Rehabil. 2009;16(4):445-450.
85. Foody JM, Rathore SS, Galusha D, et al. Hydroxymethylglutaryl-CoA reductase inhibitors in older persons with acute myocardial infarction: evidence for an age-statin interaction. J Am Geriatr Soc. 2006;54(3):421-430. (Pubitemid 43327153)
86. Schneeweiss S, Patrick AR, Stürmer T, et al. Increasing levels of restriction in pharmacoepidemiologic database studies of elderly and comparison with randomized trial results. Med Care. 2007;45(10 suppl 2):S131-S142.
87. Zhang Q, Safford M, Miller D, et al. Short-term statin exposure is associated with reduced all-cause mortality in persons with diabetes. Med Care. 2007;45(4):308-314.
88. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA. 2002;288(23):2998-3007.
89. Anderssen SA, Hjelstuen AK, Hjermann I, et al. Fluvastatin and lifestyle modification for reduction of carotid intimamedia thickness and left ventricular mass progression in drugtreated hypertensives. Atherosclerosis. 2005;178(2):387-397. (Pubitemid 40193456)
90. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364(9435):685-696. (Pubitemid 39140624)
91. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279(20):1615-1622. (Pubitemid 28248586)
92. Furberg CD, Adams HP Jr, Applegate WB, et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation. 1994;90(4):1679-1687. (Pubitemid 24320914)
93. Knopp RH, d'Emden M, Smilde JG, et al. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN). Diabetes Care. 2006;29(7):1478-1485. (Pubitemid 44127567)
94. Nakamura H, Arakawa K, Itakura H, et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet. 2006;368(9542):1155-1163. (Pubitemid 44444932)
95. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195-2207.
96. Salonen R, Nyyssönen K, Porkkala E, et al. Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation. 1995;92(7):1758-1764.
97. Sever PS, Dahlö f B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361(9364): 1149-1158. (Pubitemid 36398384)
98. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333(20):1301-1307.
99. Danaei G, Garca Rodriguez LA, Cantero OF, et al. Observational data for comparative effectiveness research: an emulation of randomized trials of statins for primary prevention of coronary heart disease [published online ahead of print October 19, 2011]. Stat Methods Med Res. (doi: 10.1177/0962280211403603).
100. Seeger JD, Williams PL, Walker AM. An application of propensity score matching using claims data. Pharmacoepidemiol Drug Saf. 2005;14(7):465-476. (Pubitemid 40990742)
101. Gardette V, Bongard V, Dallongeville J, et al. Ten-year allcause mortality in presumably healthy subjects on lipidlowering drugs (from the Prospective Epidemiological Study of Myocardial Infarction [PRIME] prospective cohort). Am J Cardiol. 2009;103(3):381-386.
102. Lemaitre RN, Psaty BM, Heckbert SR, et al. Therapy with hydroxymethylglutaryl coenzyme A reductase inhibitors (statins) and associated risk of incident cardiovascular events in older adults: evidence from the Cardiovascular Health Study. Arch Intern Med. 2002;162(12): 1395-1400. (Pubitemid 34655200)
103. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Cholesterol Treatment Trialists' (CTT) Collaboration. Lancet. 2010;376(9753):1670-1681.
104. Hernán MA, Robins JM. Authors' response, part I: observational studies analyzed like randomized experiments. Best of both worlds. Epidemiology. 2008;19(6):789-792.
105. Hernán MA, Hernández-Díaz S, Robins JM. A structural approach to selection bias. Epidemiology. 2004;15(5):615-625. (Pubitemid 40416916)
106. Horne BD, Muhlestein JB, Carlquist JF, et al. Statin therapy, lipid levels, C-reactive protein and the survival of patients with angiographically severe coronary artery disease. J Am Coll Cardiol. 2000;36(6):1774-1780.